-
公开(公告)号：US11541070B2
公开(公告)日：2023-01-03
申请号：US16714407
申请日：2019-12-13
Applicant: AMGEN INC. , Santa Maria Biotherapeutics, Inc.
Inventor： Huiquan Han , Christopher Michael Haqq , Isaac Ciechanover , Xiaolan Zhou , John Zhao-Nian Lu
IPC: A61K38/17 , A61K31/704 , A61K45/06 , A61K31/7068 , C07K16/22 , A61K39/395 , A61K39/00
Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.
-
公开(公告)号：US20190256605A1
公开(公告)日：2019-08-22
申请号：US16293254
申请日：2019-03-05
Applicant: AMGEN INC.
Inventor： Huiquan Han , Xiaolan Zhou , Qing Chen , Mei-Mei Tsai
Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
-
公开(公告)号：US20170107288A1
公开(公告)日：2017-04-20
申请号：US15247792
申请日：2016-08-25
Applicant: AMGEN INC.
Inventor： Huiquan Han , Xiaolan Zhou , Qing Chen , Mei-Mei Tsai
CPC classification number: C07K16/2863 , A61K2039/505 , C07K16/42 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
-
公开(公告)号：US20170073408A1
公开(公告)日：2017-03-16
申请号：US15346617
申请日：2016-11-08
Applicant: Amgen Inc.
Inventor： Huiquan Han , Qing Chen , Keith Soo-Nyung Kwak , Xiaolan Zhou
IPC: C07K16/22
CPC classification number: C07K16/22 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
Abstract translation: 本公开提供与抗激活素A结合蛋白（包括抗体）相关或衍生的组合物和方法。 在具体实施方案中，本公开提供了完整的人，人源化和嵌合的抗激活蛋白A抗体，其结合人激活素A，激活素A结合片段和此类抗体的衍生物，以及包含此类片段的激活素A-结合多肽。 其他实施方案提供编码此类抗体，抗体片段和衍生物和多肽的核酸，包含此类多核苷酸的细胞，制备此类抗体的方法，抗体片段和衍生物和多肽，以及使用此类抗体，抗体片段和衍生物和多肽的方法，包括方法 治疗或诊断具有激素A相关疾病或包括与性腺癌，其他癌症，类风湿性关节炎和其它疾病相关的恶病质的病症的受试者。
-
公开(公告)号：US20160152683A1
公开(公告)日：2016-06-02
申请号：US15014889
申请日：2016-02-03
Applicant: Amgen Inc.
Inventor： Huiquan Han , Keith Soo-Nyung Kwak , Xiaolan Zhou
IPC: C07K14/71
CPC classification number: C07K14/71 , C07K2319/30
Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.
Abstract translation: 本发明提供能够结合并抑制活化素A，肌生成抑制素或GDF-11的活性的新型激活素IIB5受体多肽。 本发明还提供能够产生受体多肽的多核苷酸，载体和宿主细胞。 还提供了用于治疗肌肉消瘦，代谢和其它疾病的组合物和方法。
-
Patent Agency Ranking
公开(公告)号：US20160038588A1
公开(公告)日：2016-02-11
申请号：US14777243
申请日：2014-03-14
Applicant: AMGEN INC. , PINTA BIOTHERAPEUTICS, INC.
Inventor： Ian Desmond Padhi , Huiquan Han , Christopher Michael Haqq , Isaac Ciechanover
IPC: A61K39/395 , C07K16/22 , A61K45/06
CPC classification number: A61K39/3955 , A61K9/0019 , A61K38/164 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K2319/30 , Y02A50/473
Abstract: Disclosed are methods of treating or modulating cachexia and/or increasing lean body mass and/or increasing lower extremity muscle size in a prostate cancer patient comprising administering a therapeutically effective amount of a myostatin antagonist. Further disclosed is the peptibody sequence of the myostatin antagonist, and the formulation of the peptibody.
Abstract translation: 公开了治疗或调节前列腺癌患者的恶病质和/或增加瘦体重和/或增加下肢肌肉尺寸的方法，包括施用治疗有效量的肌肉生长抑制素拮抗剂。 进一步公开了肌生成抑制素拮抗剂的肽体序列和肽体的制剂。
-
公开(公告)号：US20150322144A1
公开(公告)日：2015-11-12
申请号：US14663377
申请日：2015-03-19
Applicant: AMGEN INC.
Inventor： Huiquan Han , Taruna Arora , Qing Chen , Hsieng Sen Lu , Xiaolan Zhou
IPC: C07K16/22
CPC classification number: C07K16/26 , A61K2039/505 , C07K16/22 , C07K2317/14 , C07K2317/34 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y02A50/466
Abstract: There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them.
Abstract translation: 公开了选择性肌生成抑制素拮抗剂（包括抗体），编码它们的核酸，以及制备和使用它们的方法。
-
公开(公告)号：US20150152194A1
公开(公告)日：2015-06-04
申请号：US14407421
申请日：2013-06-11
Applicant: Amgen Inc.
Inventor： Huiquan Han , Xiolan Zhou , Qing Chen , Mei-Mei Tsai
CPC classification number: C07K16/2863 , A61K2039/505 , C07K16/42 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
Abstract translation: 本公开涉及拮抗性双重受体抗原结合蛋白，例如 抗体和使用双重受体抗体治疗病理性疾病的方法。 双重受体抗体可以包含ActRII受体的抗体，并可用于治疗病理状态。 病理状况可能包括肌肉消瘦疾病或任何需要刺激肌肉生长的疾病。
-
29.发明申请VARIANT ACTIVIN RECEPTOR POLYPEPTIDES, ALONE OR IN COMBINATION WITH CHEMOTHERAPY, AND USES THEREOF 有权各种激素受体多肽，单独或与化疗相结合，及其用途公开(公告)号：US20140348827A1
公开(公告)日：2014-11-27
申请号：US14366978
申请日：2012-12-19
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Huiquan Han , Keith Soo-Nyung Kwak , Xiaolan Zhou
IPC: A61K38/17 , A61K39/395 , A61K31/4164 , A61K45/06 , A61K31/7072
CPC classification number: A61K38/179 , A61K31/4164 , A61K31/513 , A61K31/655 , A61K31/7072 , A61K31/7088 , A61K39/395 , A61K45/06 , C07K14/71 , A61K2300/00
Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Abstract translation: 本发明提供了能够结合和抑制活化素A，肌生成抑制素或GDF-11的活性的变体激活素IIB可溶性受体多肽和蛋白质。 本发明还提供能够产生变体多肽和蛋白质的多核苷酸，载体和宿主细胞。 还提供了用于治疗肌肉消瘦等疾病和病症的组合物和方法。
-
公开(公告)号：US20140294866A1
公开(公告)日：2014-10-02
申请号：US14309590
申请日：2014-06-19
Applicant: Amgen, Inc.
Inventor： Huiquan Han , Alexander DePaoli , John Zhao-Nian Lu , Jin Lin Wang
IPC: C07K14/435 , C07K16/22
CPC classification number: C07K14/435 , A61K38/08 , A61K38/10 , C07K14/475 , C07K16/22
Abstract: The present invention provides methods for treating disorders arising from hypogonadism by administering myostatin antagonists to subjects suffering from such disorders.
Abstract translation: 本发明提供了通过将肌生长抑制素拮抗剂施用于患有这种疾病的受试者来治疗由性腺机能丧失引起的疾病的方法。
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.037 seconds)
